Breast Cancer Clinical Trials in Portland

Showing 21-40 of 336 trials

Study of Zelenectide Pevedotin in Participants With Advanced Breast Cancer

NCT06840483

This is a global, multicenter, open-label study that aims to assess the efficacy and safety of zelenectide pevedotin in participants with NECTIN4-amplified recurrent, unresectable, or metastatic breast cancer who have received prior therapy (see inclusion criteria below). The study will comprise of 2 cohorts. Cohort A will include participants with hormone receptor positive/ human epidermal growth factor receptor 2 negative \[HR+/HER2-\] breast cancer, whereas Cohort B will include participants with triple-negative breast cancer (TNBC).

Breast Cancer

BicycleTx Limited66 participantsStarted Mar 2025

Baltimore, Maryland, United States • Boston, Massachusetts, United States • St Louis, Missouri, United States +15 more locations

RECRUITINGPhase 3< 1 mile

Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer

NCT03488693

The purpose of this study is to compare the effects on low risk breast cancer receiving usual care that includes regional radiation therapy, with receiving no regional radiation therapy. Researchers want to see if not giving this type of radiation treatment works as well at preventing breast cancer from coming back.

Breast Cancer

Canadian Cancer Trials Group2,140 participantsStarted Oct 2018

Fairbanks, Alaska, United States • Gilbert, Arizona, United States • Phoenix, Arizona, United States +480 more locations

Study of Zelenectide Pevedotin in Participants With Advanced Breast Cancer

Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer

Breast Cancer Trials in Other Cities

A Phase 1/1b Study of IAM1363 in HER2 Cancers

Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer

S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer

BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia

Taxane and Taxane-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast Cancer

Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects

Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer

Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials

Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer

Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer

QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer

Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

Letrozole After Tamoxifen in Treating Women With Breast Cancer

Combination Study of SV-BR-1-GM With Retifanlimab

Other Conditions in Portland